Company size
For company-size screening, a 20–29 employee company falls below micro1’s published 30+ target. Appen must be scoped against its own eligibility description; silence is not acceptance.
Appen vs micro1
Direct licensing meets direct licensing. Neither advertised amounts nor a public seller route establish what your business will receive.
Jump to the terms ledger ↓Research comparison; limited public terms. Pair-level evidence and scenario review is pending. Published fields alone do not meet our indexing threshold. This page is noindex and absent from the sitemap, not a negative verdict.
The terms ledger.
| Criterion | Appen | micro1 |
|---|---|---|
| Operating records | Published SOPs, wikis, approval chains, support/ITSM/CRM, ERP, messaging, BI, contracts, HR/payroll Source ↗ | Published SOPs, knowledge bases, CRM, projects, QA and internal processes Source ↗ |
| Company eligibility | Published Operating or winding-down companies; no size minimum published. Source ↗ | Published 30+ employees; established documentation; English documents and representatives. Source ↗ |
| Seller geography | Unknown Not published / not established Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted. | Published US prioritized, then Western markets; strongest current demand US/UK/Canada. Global referrals do not mean global acceptance. Source ↗ |
| Published compensation | Provider claim Individually quoted by rarity, structure and history. Source ↗ | Provider claim $100k+, $500k+, $1M+ advertised partnership tiers. USD context; period unspecified; individually evaluated, not guaranteed. Source ↗ |
| Fees & net proceeds | Published No costs, setup fees or deductions. Source ↗ | Unknown Not published / not established Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted. |
| Timeline & payment trigger | Provider claim Payment on acceptance; two-business-day response is not a payout deadline. Source ↗ | Unknown Not published / not established Not established in inspected sources: No quantified payment timeline published. Ask the provider; missing terms do not establish acceptance, free fees or a payment deadline. Inspection URLs remain in the profile source list. |
| Preparation & seller effort | Published Register → NDA → written scope → extraction → representative sample sign-off → license. Source ↗ | Published Evaluation → discovery → agreed requirements → partnership. Source ↗ |
| Ownership & permitted use | Published Retains ownership. Source ↗ | Published Retains underlying ownership; approvals and scope agreed before participation. Source ↗ |
| Privacy & approval | Provider claim Read-only encrypted isolated pipelines; anonymization or synthetic rewrites; buyers/third parties do not see raw data; retention/deletion agreed before extraction. Source ↗ | Provider claim PII removed when relevant; samples reviewable; isolated processing and authorized access. Source ↗ |
| Exclusivity | Unknown Not published / not established Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted. | Unknown Not published / not established Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted. |
| Retention & deletion | Published Retention/deletion follow agreed terms; no public exact duration. Source ↗ | Published Retention/deletion follow agreed terms; no public exact duration. Source ↗ |
| HQ / published contact | Published Corporate HQ Sydney, Australia; US HQ Kirkland, Washington, according to program page. Source ↗ | Published Published privacy contact: San Francisco, US; operational HQ not independently established. Source ↗ |
Operating records
Company eligibility
Seller geography
AppenUnknown
Not published / not established
Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted.micro1Published
US prioritized, then Western markets; strongest current demand US/UK/Canada. Global referrals do not mean global acceptance.
Source ↗Published compensation
Fees & net proceeds
micro1Unknown
Not published / not established
Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted.Timeline & payment trigger
AppenProvider claim
Payment on acceptance; two-business-day response is not a payout deadline.
Source ↗micro1Unknown
Not published / not established
Not established in inspected sources: No quantified payment timeline published. Ask the provider; missing terms do not establish acceptance, free fees or a payment deadline. Inspection URLs remain in the profile source list.Preparation & seller effort
Ownership & permitted use
Privacy & approval
AppenProvider claim
Read-only encrypted isolated pipelines; anonymization or synthetic rewrites; buyers/third parties do not see raw data; retention/deletion agreed before extraction.
Source ↗micro1Provider claim
PII removed when relevant; samples reviewable; isolated processing and authorized access.
Source ↗Exclusivity
AppenUnknown
Not published / not established
Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted.micro1Unknown
Not published / not established
Not established in inspected sources. Ask for the actual agreement; unknown does not mean free, unrestricted or accepted.Retention & deletion
HQ / published contact
Which difference matters to your company?
Data fit
For your existing records, start with category fit: Appen lists SOPs, wikis, approval chains, support/ITSM/CRM, ERP, messaging, BI, contracts, HR/payroll; micro1 lists SOPs, knowledge bases, CRM, projects, QA and internal processes. Ask each which subset has active demand before preparing exports.
Payment trigger
Appen: Payment on acceptance; two-business-day response is not a payout deadline. micro1: Payment timing not established; ask the provider. These clocks measure different stages, not equivalent payout deadlines; ask for a written acceptance-to-payment interval.
Shared diligence, not shared guarantees.
Both routes need lawful rights to the material. Removing names does not remove confidentiality obligations or re-identification risk. Require sample approval, buyer-use restrictions, precise payment triggers and downstream retention/deletion terms.
Seller-outcome evidence
Appen: No independently audited operating-business payout established in this research. Provider cases and partnership confirmations do not establish a typical seller outcome.
micro1: No independently audited operating-business payout established in this research. Provider cases and partnership confirmations do not establish a typical seller outcome.